ACAD
EquityACADIA Pharmaceuticals Inc.
Health Care · Biotechnology
$22.50
+22.50 (+0.00%)
Open
N/A
Day Range
$22.28 - $22.96
52W Range
$13.40 - $28.35
Volume
2M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Teases Key Phase 2 Data in 2025
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) Therapeutic Domains
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | $233.86 | N/A | 2.84% | +0.00% |
| CRSP | CRISPR Therapeutics AG | $58.06 | N/A | - | +0.00% |
| AHCO | AdaptHealth Corp. | $9.40 | N/A | - | +0.00% |
| A | Agilent Technologies, Inc. | $119.04 | N/A | 0.84% | +0.00% |
| ACB | Aurora Cannabis Inc. | $3.48 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $7,870.00 | N/A | 5.59% | +0.00% |
| ABCL | AbCellera Biologics Inc. | $3.71 | N/A | - | +0.00% |
| ABT | Abbott Laboratories | $114.12 | N/A | 2.10% | +0.00% |
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
www.acadia.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for ACAD
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for ACAD.